Innovative Pharma Remedies Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 09-12-2024
- Paid Up Capital ₹ 0.40 M
as on 09-12-2024
- Company Age 11 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2021)
- Profit -36.36%
(FY 2021)
- Ebitda -36.36%
(FY 2021)
- Net Worth -4.95%
(FY 2021)
- Total Assets -42.19%
(FY 2021)
About Innovative Pharma Remedies
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.40 M, as per Ministry of Corporate Affairs (MCA) records.
Rudra Hota and Dipti Senapati serve as directors at the Company.
- CIN/LLPIN
U24100OR2013PTC016778
- Company No.
016778
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Apr 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Cuttack
Industry
Company Details
- Location
Khorda, Odisha, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Innovative Pharma Remedies?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rudra Hota  | Director | 25-Apr-2013 | Current |
| Dipti Senapati | Director | 25-Apr-2013 | Current |
Financial Performance of Innovative Pharma Remedies.
Innovative Pharma Remedies Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 36.36% decrease in profit. The company's net worth dipped by a decrease of 4.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Innovative Pharma Remedies?
In 2019, Innovative Pharma Remedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Odisha Shrimp Trading & Exports Private LimitedActive 8 years 11 months
Rudra Hota and Dipti Senapati are mutual person
- Shree Raghuveer Infraprojects Private LimitedActive 13 years 8 months
Rudra Hota and Dipti Senapati are mutual person
- Shree Mahaveer Pharma-Tech And Drugs Private LimitedActive 13 years 10 months
Rudra Hota is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Innovative Pharma Remedies?
Unlock and access historical data on people associated with Innovative Pharma Remedies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Innovative Pharma Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Innovative Pharma Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
